

**WHO Validation meeting on hepatitis elimination as a public health threat: Part 1
29-30 June Half-day Virtual meeting**

PROVISIONAL AGENDA

DAY 1: SETTING THE SCENE (Co-Chairs: Ramatoulie Njie (Gambia) and Ben Cowie (Australia))		
TIME	AGENDA ITEM	SPEAKERS
Session 1: Introduction and objectives		
13.00-14.30	Welcome remarks (10 m)	Ren Minghui/Meg Doherty/Andrew Ball
	Introductions (10 m)	Co-Chairs
	Meeting overview - Objectives, expected outcomes, methods, review of agenda and background documents (10 m)	Philippa Easterbrook (WHO HQ)
	Introduction to framework guidance for elimination of viral hepatitis (5m)	Nick Walsh (WHO consultant)
	Setting the scene - Global and regional progress towards elimination (5m)	Fuqiang Cui (WHO HQ)
	Overview of country preparedness for validation of HBV and HCV elimination – what do countries have or not? (10m) – <u>Background Paper 1</u>	Homie Razavi (CDA) and Muazzam Nasrullah (CDC)
	Group discussion (40m)	Co-Chairs
Session 2: Examples of validation of elimination for other diseases - Processes used, experiences and lessons learned		
14.30 –15.45	WHO multi-disease elimination initiative and overview of different certification, verification and validation processes and definitions used (10m)	Richard Carr (ADG/WHO HQ)
	Malaria (10m)	Kim Lindblade (GMP/WHO HQ)
	GVAC (Perinatal HIV and Syphilis) (10 m)	Angela Mushavi (GVAC chair/Zimbabwe MOH)
	HBV control through immunization and PMTCT in WPRO and PAHO (15m)	Polin Chan/Anne Brink (WPRO) Leandro Sereno/Alba Roperio (PAHO)
	Group discussion: Lessons learned for hepatitis elimination (30m)	Co-Chairs
15.45-15.50	BREAK	
Session 3: Global progress with HBV EMTCT		
15.50-16.30	2018 regional HBsAg prevalence in 5 year olds and in general population (5m)	Ximena Riveros Balta (WHO HQ)
	Progress on meeting the GHSS 2030 for elimination of HBV through immunization (10m)	Shalini Desai (IVB/WHO HQ)
	Overview of current and modelled 2030 HBV EMTCT situation (5m)	Home Razavi (CDA)
	Key questions and Group Discussion (20m)	Co-Chairs
Session 4: Introduction to HBV EMTCT Criteria and Rationale — <u>Background Paper 2</u>		
16.00 – 17.30	Proposed criteria for elimination and path to elimination, rationale and regional perspectives (10m)	Philippa Easterbrook (WHO HQ)
	Modelling to support impact/programme criteria (10m)	Shevanthi Nagayam (Imperial College)
	<ul style="list-style-type: none">Group Discussion: Elimination criteria (30m)Group Discussion: Path to elimination criteria (30m)	Co-Chairs

DAY 2: Validation of HBV EMTCT (Co-Chairs: Ramatoulie Njie (Gambia) and Ben Cowie (Australia))		
13.00- 13.10	Debrief Day 1 and Introduction to Day 2	Co-Chairs
Session 5: Process and Governance — <u>Background Paper 2</u>		
13:10 – 14.10	Proposed options for integration with HIV/syphilis EMTCT and overall hepatitis elimination validation process (10m)	Morkor Newman (WHO HQ)/Nick Walsh
	Country validation case studies ((HIV/syphilis) and lessons learned (10m)	MOH Malaysia and MOH Cuba (TBC)
	Key questions and Group discussion (30m)	Co-Chairs
Session 6: Measuring impact indicators – HBsAg prevalence in 5 year olds and MTCT rate – <u>Background paper 3</u>		
14:10 – 15.10	Introduction to different approaches for assessing HBV incidence (8m)	Shevanthi Nagayam (Imperial College)
	HBV incidence and MTCT measurement – China experience with national serosurveys, testing in pregnant woman and PVST (10m)	TBC (China CDC)
	Multistage survey experience in Colombia (10m)	Cielo Rios (Colombia MOH)
	Key questions and Group Discussion (20m)	Co-Chairs
15.10-15.15	BREAK	
Session 7: Measuring service/programmatic coverage - immunizations and PMTCT – <u>Background paper 3</u>		
15:15 – 16.10	Measuring Immunization coverage and PMTCT (10m)	Minal Patel/Julien Kabore (IVB WHO HQ/AFRO)
	Measuring testing and PMTCT coverage - HIV/syphilis (8m)	M Taylor (WHO HQ)
	Use of modelling for assessing validation (8m)	Homie Razavi (CDA)
	Key questions and Group Discussion (20m)	Co-Chairs
Session 8: Other implementation considerations including human rights and equity - <u>Background paper 2</u>		
16.10 - 17:00	Overview of implementation considerations including equity, human rights and community engagement (15m)	Niklas Luhmann (WHO HQ)/Polin Chan (WPRO)/Funmi Lesi (AFRO) and discussants
	Key questions and Group discussion (30m)	Co-Chairs
Session 9: Final proposal for HBV EMTCT and Next steps for validation of elimination process		
17:00 - 17:30	Summary of key discussion points and consensus on key elements of draft guidance (criteria and rationale; process; and measurement)	Ramatoulie Njie and Ben Cowie
	Next steps: Future meeting, guidance documents and pilot testing in selected countries	Philippa Easterbrook
	Closing remarks	Meg Doherty/Andrew Ball